Associate Editor-in-Chief

Ling Lu, MD, PhD

Dr. Ling Lu is Division of Liver Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Prof. Ling Lu is a surgeon at Division of Liver Surgery, First Affiliated Hospital of Nanjing Medical University, Nanjing, China. He is involved in researches concerning liver surgery and transplantation immunology. In the past 15 years, Prof. Lu focuses on the immunology of liver transplantation, especially on the clinical application of regulatory T cells for transplant patients. In the past 5 years, some of these studies have been translated into the clinic for the patients after living donor liver transplantation surgery.

He has peer reviewed many publications for main scientific journals, such as Plos one, Lancet Global Health, Journal of Cellular and Molecular Medicine, and Grant reviews of National Science Foundation of China (NSFC).

Binghe Xu, Prof., MD, PhD

Dr. Binghe Xu is Professor and Director of the Department of Medical Oncology at the Cancer Hospital and Institute, Chinese Academy of Medical Sciences (CAMS), and Peking Union Medical College (PUMC) in Beijing, China. He received his Doctorate of Philosophy and Master of Science degree in oncology from the Peking Union Medical College, and his Doctorate of Medicine from Wuhan University Medical College, China.

His major interests are in basic and clinical research of solid tumors, especially breast cancer, as well as clinical trials of new anticancer agents. He has participated more than 60 clinical trials as PI. Currently, he is the executive steering committee (EC) and steering committee (SC) members of several global clinical trials. Dr. Xu has published 240 papers in peer reviewed oncology journals mainly with respect to breast diseases and clinical trials of anticancer agents.

Dr. Xu is member of several current societies, including Chairman of Chinese Breast Cancer Society (CSBC); Member of American Society of Clinical Oncology (ASCO); and Member of Pharmacopoeia Commission of People's Republic of China (ChPC), etc.